CM
BBIO icon

Crestline Management’s BridgeBio Pharma BBIO Stock Holding History

Crestline Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-44,740
Closed -$1.23M – 72
2024
Q4 		$1.23M Buy
44,740
+11,169
+33% +$289K 0.04% 379
2024
Q3 		$855K Buy
+33,571
New +$881K 0.04% 290

Other funds holding BBIO

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Crestline Management's BBIO Position: Q1 2025 in Review

Crestline Management sold out of BridgeBio Pharma (BBIO) in Q1 2025, closing a stake of 44,740 shares — an estimated $1.23M sold.

Crestline Management first reported a position in BBIO in Q3 2024 and held it in 2 quarters. The position peaked at $1.23M in Q4 2024. 304 funds tracked by Wall St. Rank hold BBIO as of Q1 2025.

  • Crestline Management reported no remaining BridgeBio Pharma position as of Q1 2025 after selling out during the quarter.
  • Crestline Management sold 44,740 BridgeBio Pharma shares in Q1 2025, an estimated $1.23M.
  • Crestline Management first reported a position in BridgeBio Pharma in Q3 2024 and held it in 2 quarters.
  • Crestline Management's BridgeBio Pharma position peaked at $1.23M in Q4 2024.
  • 304 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2025.

Based on Crestline Management's 13F filing for Q1 2025, filed 15 May 2025.